Cyfuse Biomedical K.K.

Tokyo Stock Exchange 4892.T

Cyfuse Biomedical K.K. Total Non-Current Liabilities for the year ending December 31, 2023: USD 2.45 M

Cyfuse Biomedical K.K. Total Non-Current Liabilities is USD 2.45 M for the year ending December 31, 2023, a -11.65% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Cyfuse Biomedical K.K. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 2.77 M, a -11.45% change year over year.
  • Cyfuse Biomedical K.K. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 3.13 M, a -26.59% change year over year.
  • Cyfuse Biomedical K.K. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 4.26 M.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
Tokyo Stock Exchange: 4892.T

Cyfuse Biomedical K.K.

CEO Ms. Shizuka Akieda
IPO Date Dec. 1, 2022
Location Japan
Headquarters Sumitomo Fudosan Mita Twin Building
Employees 21
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email